3 completed, 1 active not recruiting, 1 no longer available, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow nedosiran: new trials by email Literature Review of nedosiran trials Research Report on nedosiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function nedosiran - Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 | Phase 2 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 27 | 2022-02-22 | 2026-04-16 |
| Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD DCR-PHXC - Primary Hyperoxaluria Type 1, End Stage Renal Disease | Phase 2 | Recruiting | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 28 | 2021-04-15 | 2025-12-24 |
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 3 | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 | 2020-09-14 | 2024-09-19 |
| A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) | Phase 2 | Completed | Novo Nordisk A/S | 35 | 2019-10-28 | 2024-05-22 |
| Long Term Extension Study in Patients With Primary Hyperoxaluria DCR-PHXC - Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) | Phase 3 | Active not recruiting | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 75 | 2019-07-09 | 2026-10-08 |
| Treatment of Primary Hyperoxaluria Type 1 With Nedosiran Nedosiran - Primary Hyperoxaluria Type 1 (PH1) | No longer available | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2025-07-22 |
Primary hyperoxaluria type 1 (5) · Hyperoxaluria, Primary (4) · Primary hyperoxaluria type 2 (3) · Genetic Diseases, Inborn (2) · Kidney Diseases (2) · Urologic Diseases (2) · Kidney Failure, Chronic (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (5) · Novo Nordisk A/S (1)
Germany (5) · United Kingdom (5) · United States (5) · Italy (4) · Lebanon (4) · Spain (4) · Canada (3) · France (3) · Japan (3) · Netherlands (3) · Australia (2) · Poland (2) · Romania (2) · Turkey (Türkiye) (2) · United Arab Emirates (2)
Alexandra Haagensen, MD, MBA (1) · Sarb Shergill, PhD (1) · Verity Rawson, MB.CHB (1)